GAO Chides FDA For Prioritizing Foreign Inspections Based On Pre-approval Concerns
Executive Summary
The Government Accountability Office’s latest assessment of FDA’s foreign drug inspections program takes the agency to task for failing to implement a new prioritization scheme that GAO recommended two years ago.
You may also be interested in...
FDASIA Study Mandates Focus On Performance, But Could Slow Reviews
Advocates for the agency worry that while each of the performance assessments seems reasonable individually, together the reports could burden staff to the point of pulling some from application reviews or other tasks to help complete them.
FDA Ups Foreign Inspections In FY ’07; Visits 11% Of Foreign Establishments
FDA inspected more foreign drug establishments in fiscal 2007 than in each of the five previous years, but visited less than 11 percent of such facilities, the Government Accountability Office estimates in a report released Oct. 22
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.